Johns Hopkins Bloomberg School of Public Health

Majority of First-Wave COVID-19 Clinical Trials Have Significant Design Shortcomings, Study Finds

Analysis of COVID-19 clinical trials as of late March finds quantity but less quality

Newswise — Most of the registered clinical trials of potential treatments for COVID-19 underway as of late March were designed in ways that will greatly limit their value in understanding potential treatments, according to a study from researchers at Johns Hopkins Bloomberg School of Public Health.

The researchers, whose findings appear June 9 in the journal BMJ Open, analyzed the 201 clinical trials for drugs or plasma that, as of March 26, had been registered in the U.S. under ClinicalTrials.gov and in the international clinical trials registry maintained by the World Health Organization (WHO). Of the trials analyzed in this early snapshot, 100 (49.8 percent) were registered in China and 78 (37.8 percent) in the U.S. The majority of trials in the U.S. clinical trials registry were registered from international researchers. Among the 201 trials analyzed, 126 were recruiting participants from China, 31 from Europe, 14 from the U.S.

The analysis found that one-third of trials lacked clinical endpoints to clearly define success or failure. Nearly one-half were designed to enroll fewer than 100 patients, limiting their usefulness to assess modestly-sized treatment benefits. Two-thirds were “open label,” meaning that patients and doctors were aware who did and didn’t receive the treatment—in principle, allowing their unconscious expectations to influence the results. ”Because of these weaknesses, many of these studies are likely to yield only preliminary evidence,” says study first author Hemalkumar Mehta, PhD, an assistant professor in the Department of Epidemiology at the Bloomberg School. “Given the urgency of identifying definitive evidence on potential COVID-19 treatments, this is an instance where we wish we did not have to say ‘further research is needed’ because of basic trial design shortcomings and small trials.”

The rapid initiation of so many clinical trials reflects the lack of any effective treatment for acute COVID-19 disease, whose global toll exceeds 400, 857 deaths worldwide as of June 8, 2020, according to the World Health Organization’s situation report. Of the 201 trials the researchers analyzed in their paper, the vast majority involved treatments already used for other diseases—treatments that could potentially be repurposed for COVID-19 relatively quickly because they have existing safety profiles and have already been evaluated by the U.S. Food and Drug Administration or other regulators around the globe. U.S. doctors generally have wide discretion to prescribe FDA-approved drugs for other, “off- label” conditions. The authors note that off-label use can carry risks, and it is essential that therapies, including those used off-label, are studied for safety and effectiveness for COVID-19.

In all, the 201 trials involved 92 distinct drugs as well as antibody-containing blood plasma.

Mehta and colleagues found that most of these trials demonstrated design weaknesses. For example, about a third had no defined clinical endpoint, such as hospital discharge or survival, by which success could be measured. About a quarter lacked the standard random assignment of patients to a candidate treatment or control/comparator drug. Of the 152 trials that did randomize patients to a treatment or comparator, only 55 involved the usual practice of ‘blinding’—a bias-reducing strategy in which patients as well as doctors and others who direct care and assess outcomes are kept from knowing who received the treatment or placebo.

“We understand the urgency of clinical research on COVID-19, but this is a time when we need rigorous science to inform policy and clinical decision-making,” says study senior author G. Caleb Alexander, MD, professor in the Department of Epidemiology at the Bloomberg School. “Any treatment that is ultimately deemed safe and effective via robust trials could potentially be used by millions of people.”

The researchers noted that the number of U.S.- or WHO-registered clinical trials of potential COVID-19 treatments tripled from the beginning of March to March 26 when they did their snapshot survey, and since March 26 has risen to more than 2,000 registered trials as of June 8, 2020, as new trials are registered on a daily basis.

“As the safety and effectiveness of new treatments are evaluated, it’s vital that we use the best science to do so,” Mehta says. “It’s especially important at this juncture with many lives in the balance.”

“Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis” was written by Hemalkumar B. Mehta, Stephan Ehrhardt, Thomas J. Moore, Jodi Segal, and G. Caleb Alexander.

Disclosure: Alexander is past chair of the FDA’s Peripheral and Central Nervous System Advisory Committee; has served as a paid advisor to IQVIA; is a co-founding principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx’s National P&T Committee.




Filters close

Showing results

110 of 2482
Released: 7-Jul-2020 5:25 PM EDT
Lung physiology and immune function in children could be protecting them from severe COVID-19
University of Texas Health Science Center at Houston

Differences in lung physiology and immune function in children could be why they are more often spared from severe illness associated with COVID-19 than adults, according to pediatric and adult physicians at UTHealth and Baylor College of Medicine, who teamed up to investigate the disparity.

Newswise: ACI Launches “Healthy Returns”: New Toolkit Contains Important Cleaning, Hygiene Reminders for Reopened Businesses and Offices
Released: 7-Jul-2020 5:15 PM EDT
ACI Launches “Healthy Returns”: New Toolkit Contains Important Cleaning, Hygiene Reminders for Reopened Businesses and Offices
American Cleaning Institute

As communities across the nation begin the reopening process stemming from the coronavirus (COVID-19) pandemic, the American Cleaning Institute (ACI) announced the roll-out of Healthy Returns, a free online toolkit for small businesses and offices containing concise, easy to understand reminders on hygiene, cleaning and disinfecting that are crucial to keeping the workplace healthy and safe.

access_time Embargo lifts in 2 days
Embargo will expire: 10-Jul-2020 1:00 AM EDT Released to reporters: 7-Jul-2020 3:00 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 10-Jul-2020 1:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 7-Jul-2020 2:45 PM EDT
COVID-19 in Patients Who Have Received Kidney Transplants or Are Undergoing Dialysis
American Society of Nephrology (ASN)

• A recent study found that most kidney transplant recipients with COVID-19 do not need to be hospitalized. • Another study found that patients on dialysis who develop COVID-19 may have symptoms that are different from other patients with the infectious disease.

Released: 7-Jul-2020 2:05 PM EDT
Law clinic wins access to COVID-19 race data
Cornell University

The First Amendment Clinic at Cornell Law School, working on behalf of its client, The New York Times, helped secure the release of previously unseen data that provides the most detailed look yet at nearly 1.5 million American coronavirus patients from 974 counties across the country.

Released: 7-Jul-2020 2:00 PM EDT
Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors (PPIs)
American College of Gastroenterology (ACG)

Findings from an online survey of more than 53,000 American adults suggest that using heartburn medications known as proton pump inhibitors (PPIs) once or twice daily significantly increases the odds of a positive test for COVID-19 compared to those who do not take PPIs. This research appeared online July 7, 2020 in pre-print format in The American Journal of Gastroenterology.

Released: 7-Jul-2020 1:40 PM EDT
COVID-related discrimination disproportionately impacts racial minorities, study shows
University of Southern California (USC)

Discrimination against people thought to be infected with coronavirus was experienced by a rising number of United States residents, particularly racial minorities, in the early stages of the COVID-19 pandemic, according to a new study from the USC Dornsife College of Letters, Arts and Sciences.

Newswise: 236726_web.jpg
Released: 7-Jul-2020 1:10 PM EDT
A chemical cocktail of air pollution in Beijing, China during COVID-19 outbreak
Institute of Atmospheric Physics, Chinese Academy of Sciences

The novel coronavirus disease (COVID-19) spreads rapidly around the world, and has limited people's outdoor activities substantially.

Released: 7-Jul-2020 12:50 PM EDT
Remdesivir can save more lives where ICUs are overwhelmed
Boston University School of Medicine

Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs).

Newswise: Cedars-Sinai Named Age-Friendly Health System
Released: 7-Jul-2020 12:40 PM EDT
Cedars-Sinai Named Age-Friendly Health System
Cedars-Sinai

Shortly after COVID-19 was declared a pandemic, more than 450 older adults learned their weekly exercise classes offered through the Cedars-Sinai Geriatrics Program were on hold. But under the quick-thinking direction of geriatrician Allison Moser Mays, MD, the program pivoted, creating a way for seniors to access live classes over Zoom from the comfort of their homes. The online format has proved especially popular.


Showing results

110 of 2482

close
0.99936